Determination of Regulatory Review Period for Purposes of Patent Extension; ENSPRYNG; Correction
Primary source
Metadata and text below are from the Federal Register, a public-domain U.S. government work. Always verify the official published version before relying on it for any legal matter.
Issuing agencies
Abstract
The Food and Drug Administration (FDA or the Agency) is correcting a notice that appeared in the Federal Register of July 13, 2022. The document determined the regulatory review period for ENSPRYNG. After review of a timely request for reconsideration by the applicant of the calculation of the applicable regulatory review period of the biologic product ENSPRYNG in that notice, FDA has determined that a revision of the supplementary information section is warranted. This notice corrects the applicable regulatory review period language.
Full Text
<html>
<head>
<title>Federal Register, Volume 88 Issue 100 (Wednesday, May 24, 2023)</title>
</head>
<body><pre>
[Federal Register Volume 88, Number 100 (Wednesday, May 24, 2023)]
[Notices]
[Page 33614]
From the Federal Register Online via the Government Publishing Office [<a href="http://www.gpo.gov">www.gpo.gov</a>]
[FR Doc No: 2023-10979]
=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket Nos. FDA-2020-E-2361; FDA-2020-E-2362; and FDA-2020-E-2363]
Determination of Regulatory Review Period for Purposes of Patent
Extension; ENSPRYNG; Correction
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice; correction.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA or the Agency) is
correcting a notice that appeared in the Federal Register of July 13,
2022. The document determined the regulatory review period for
ENSPRYNG. After review of a timely request for reconsideration by the
applicant of the calculation of the applicable regulatory review period
of the biologic product ENSPRYNG in that notice, FDA has determined
that a revision of the supplementary information section is warranted.
This notice corrects the applicable regulatory review period language.
FOR FURTHER INFORMATION CONTACT: Beverly Friedman, Office of Regulatory
Policy, Food and Drug Administration, 10903 New Hampshire Ave., Bldg.
51, Rm. 6250, Silver Spring, MD 20993, 301-796-3600.
SUPPLEMENTARY INFORMATION: In the Federal Register of July 13, 2022 (87
FR 41724), on page 41725, in the second column, under ``II.
Determination of Regulatory Review Period,'' the first two sentences
should be corrected to read as follows: ``FDA has determined that the
applicable regulatory review period for ENSPRYNG is 2,494 days. Of this
time, 2,128 days occurred during the testing phase of the regulatory
review period, while 366 days occurred during the approval phase.''
Dated: May 18, 2023.
Lauren K. Roth,
Associate Commissioner for Policy.
[FR Doc. 2023-10979 Filed 5-23-23; 8:45 am]
BILLING CODE 4164-01-P
</pre></body>
</html>This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.